Name | TL-895 |
---|
Description | TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively[1]. TL-895 is used be for JAKi-relapsed/refractory myelofibrosis, acute myeloid leukemia, COVID-19 and cancer research[2][3][4]. |
---|---|
Related Catalog | |
Target |
IC50: 1.5 nM; Ki: 11.9 nM (BTK)[1] |
References |
Molecular Formula | C25H26FN5O2 |
---|---|
Molecular Weight | 447.50 |